妇产科指南

订阅

MedSci主页 / 所有栏目 / 妇产科指南

中成药治疗更年期综合征临床应用指南（2020年）

2021-04-30 中国中西医结合杂志.2021.41(4):418-426.

更年期综合症

本指南为临床一线的西医、中西医结合专科和中医医师及基层医院医师治疗更年期综合征提供中成药选择使用的原则和指导， 对提高中成药治疗更年期综合征患病人群的临床疗效和合理使用中成药具有重要的指导意义。

中文标题：

中成药治疗更年期综合征临床应用指南（2020年）

发布机构：

发布日期：

2021-04-30

简要介绍：

本指南为临床一线的西医、中西医结合专科和中医医师及基层医院医师治疗更年期综合征提供中成药选择使用的原则和指导， 对提高中成药治疗更年期综合征患病人群的临床疗效和合理使用中成药具有重要的指导意义。

相关资料下载：
[AttachmentFileName(sort=1, fileName=中成药治疗优势病种临床应用指南.pdf)] GetToolGuiderByIdResponse(projectId=1, id=33dde1c00210063c, title=中成药治疗更年期综合征临床应用指南（2020年）, enTitle=, guiderFrom=中国中西医结合杂志.2021.41(4):418-426., authorId=0, author=, summary=本指南为临床一线的西医、中西医结合专科和中医医师及基层医院医师治疗更年期综合征提供中成药选择使用的原则和指导， 对提高中成药治疗更年期综合征患病人群的临床疗效和合理使用中成药具有重要的指导意义。, cover=https://img.medsci.cn/2021518/1621269175914_2020535.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Fri Apr 30 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>本指南为临床一线的西医、中西医结合专科和中医医师及基层医院医师治疗更年期综合征提供中成药选择使用的原则和指导， 对提高中成药治疗更年期综合征患病人群的临床疗效和合理使用中成药具有重要的指导意义。</p> </div> </div> </div>, tagList=[TagDto(tagId=28305, tagName=更年期综合症)], categoryList=[CategoryDto(categoryId=36, categoryName=妇产科, tenant=100), CategoryDto(categoryId=37, categoryName=中医科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=28305, guiderKeyword=更年期综合症, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=10258, appHits=178, showAppHits=0, pcHits=720, showPcHits=10079, likes=0, shares=19, comments=5, approvalStatus=1, publishedTime=Tue May 18 00:40:50 CST 2021, publishedTimeString=2021-04-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue May 18 00:33:08 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Mon Jan 01 22:16:56 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=中成药治疗优势病种临床应用指南.pdf)])
中成药治疗优势病种临床应用指南.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1056995, encodeId=47c0105699544, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45f65265452, createdName=1480f9f2m86暂无昵称, createdTime=Sat Oct 02 21:06:21 CST 2021, time=2021-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010468, encodeId=42a01010468b0, content=感谢分分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=332a2318615, createdName=yeyekeke, createdTime=Mon Aug 23 02:26:13 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973542, encodeId=f2759e3542ff, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e8a5480521, createdName=ms8000000656093431, createdTime=Mon Jun 14 20:41:40 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2021-10-02 1480f9f2m86暂无昵称

    感谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1056995, encodeId=47c0105699544, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45f65265452, createdName=1480f9f2m86暂无昵称, createdTime=Sat Oct 02 21:06:21 CST 2021, time=2021-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010468, encodeId=42a01010468b0, content=感谢分分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=332a2318615, createdName=yeyekeke, createdTime=Mon Aug 23 02:26:13 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973542, encodeId=f2759e3542ff, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e8a5480521, createdName=ms8000000656093431, createdTime=Mon Jun 14 20:41:40 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2021-08-23 yeyekeke

    感谢分分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1056995, encodeId=47c0105699544, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45f65265452, createdName=1480f9f2m86暂无昵称, createdTime=Sat Oct 02 21:06:21 CST 2021, time=2021-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010468, encodeId=42a01010468b0, content=感谢分分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=332a2318615, createdName=yeyekeke, createdTime=Mon Aug 23 02:26:13 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973542, encodeId=f2759e3542ff, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e8a5480521, createdName=ms8000000656093431, createdTime=Mon Jun 14 20:41:40 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2021-06-14 ms8000000656093431

    感谢分享

    0

相关指南

国际中医临床实践指南：更年期综合征

世界中医药学会联合会 · 2020-01-25

拓展阅读

国际中医临床实践指南：更年期综合征

世界中医药学会联合会 · 2020-01-25

2021 NAMS立场声明：绝经后女性骨质疏松症的管理

北美绝经学会(NAMS,The North American Menopause Society) · 2021-08-28

2022 ACOG临床实践指南：绝经后骨质疏松症的管理（No.2）

美国妇产科医师学会(ACOG,American College of Obstetricians and Gynecologists) · 2022-04-01

更年期症状及其决定因素的跨文化比较方法概述：加强更年期和衰老报告 (STRROMA) 研究的指南

Equator Network · 2022-09-01

【中文译文】2022 ACOG临床实践指南：绝经后骨质疏松症的管理（No.2）

美国妇产科医师学会(ACOG,American College of Obstetricians and Gynecologists) · 2022-04-01